News Search Results
Jul 29, 2025, 09:12 ET Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
diseases across the lifespan. By utilizing Alamar's NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel's ability to distinguish brain-derived phosphorylated
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
diseases across the lifespan. By utilizing Alamar's NULISAseq CNS Disease Panel 120, researchers will be able to measure hundreds of brain-related proteins from minimal blood volumes, with exceptional sensitivity and specificity. Notably, the CNS panel's ability to distinguish brain-derived phosphorylated
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 09:12 ET Alamar Biosciences y el DZNE se asocian para un estudio de perfil proteómico
hoy una colaboración estratégica con el Centro Alemán de Enfermedades Neurodegenerativas (DZNE) para implementar sus paneles ultrasensibles NULISAseq™ CNS Disease Panel 120 y Inflammation Panel 250 en el Estudio Rhineland, una de las cohortes longitudinales de envejecimiento más completas e innovadoras
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 08:03 ET NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025
Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiatrist who has been a pioneer in the understanding
More news about: NRx Pharmaceuticals, Inc.
Jul 29, 2025, 06:29 ET Alamar Biosciences prezentuje průkopnická data o mozkovém pTau proteinu na Mezinárodní konferenci asociace pro Alzheimerovu chorobu (AAIC)
Prezentace představí data z kohorty osob narozených v roce 1946 včetně hladiny nových izoforem mozkového pTau, stanovené pomocí testovacího panelu NULISAseq™ CNS Disease Panel 120 v presymptomatických vzorcích i vzorcích získaných po stanovení diagnózy AD (Alzheimerovy choroby), přičemž zdůrazní vynikající schopnost
More news about: Alamar Biosciences, Inc.
Jul 29, 2025, 02:27 ET Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing
nucleic acid design and the development of circular and condensed structures to improve stability and tissue distribution.- Non-Hepatic and CNS Targeting: New delivery strategies based on glycosylated carriers and ring-shaped condensation mechanisms demonstrated promise in crossing physiological
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 29, 2025, 02:15 ET Tsingke Biotech Hosts 2025 Small Nucleic Acid Therapeutics Roundtable in Beijing
nucleic acid design and the development of circular and condensed structures to improve stability and tissue distribution.- Non-Hepatic and CNS Targeting: New delivery strategies based on glycosylated carriers and ring-shaped condensation mechanisms demonstrated promise in crossing physiological
More news about: Beijing Tsingke Biotech Co., Ltd.
Jul 28, 2025, 22:28 ET Alamar Biosciences представляет передовые данные о тау-белках, полученных из тканей мозга, на Международной конференции Ассоциации Альцгеймера (AAIC)
презентации будут представлены данные по когорте 1946 года рождения, включающие новые изоформы pTau в мозге, полученные с помощью панели NULISAseq™ CNS Disease Panel 120 как в пресимптомных, так и в диагностических выборках, что подчеркивает превосходную способность фосфорилированных тау-белков, полученных
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 21:00 ET Alamar Biosciences社、アルツハイマー病協会国際会議（AAIC）で先駆的な脳由来pTauデータを展示
脳由来pTauのパフォーマンス：このプレゼンテーションでは、1946年生まれのコホートから得られたデータを紹介し、発症前とAD診断後の両方のサンプルでNULISAseq™ CNS Disease Panel 120を使用した新しい脳由来pTauアイソフォームを取り上げ、脳由来pTauが診断される何年も前にアルツハイマーを予測する優れた能力を強調します。病気の進行との相関関係：データは脳由来のpTauレベルとアミロイドおよびTau PET画像との相関関係を示します神経病理およびADの併存病理のバイオマーカー：NULISAseq™ CNS Disease Panel 120を使用して剖検により病状が確認された患者の独自のコホートを解析した結果、神経病理とADの併存病理を検出するためのバイオマーカーが特定されました。前臨床研究：NULISAseq™
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 15:10 ET Alamar Biosciences Perlihatkan Rintisan Data pTau yang Berasal dari Otak di Alzheimer's Association International Conference (AAIC)
Otak: Presentasi ini akan menyampaikan data dari Kelompok Kelahiran tahun 1946 yang menampilkan isoform pTau yang berasal dari otak dengan menggunakan NULISAseq ™ CNS Disease Panel 120 pada sampel diagnosis pra gejala dan pasca Penyakit Alzheimer, dengan menyoroti keunggulan kemampuan pTau yang berasal dari otak dalam
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 14:08 ET Alamar Biosciences prezentuje priekopnícke dáta o tau proteíne odvodenom z mozgu na Medzinárodnej konferencii asociácie pre Alzheimerovu chorobu (AAIC)
údajov generovaných platformou NULISA na meranie tau proteínov odvodených z mozgu spolu s viac ako 120 kľúčovými proteínmi súvisiacimi s ochoreniami CNS. Tento úspech by mohol urýchliť včasnú detekciu aj terapeutické monitorovanie Alzheimerovej choroby a súvisiacich neurodegeneratívnych ochorení.
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 13:49 ET Qynapse Releases Data Highlighting the Accuracy of QyScore® and Predictive performance of QyPredict® for Disease Progression in preclinical Alzheimer's Disease
commercializing an AI-powered and proprietary neuroimaging software platform, creating the potential for earlier clinical precision on the frontlines of CNS disease. Qynapse's flagship solution, QyScore®, FDA-Cleared and CE-Marked, adds the potential for more precise and objective brain scan analysis. Qynapse
More news about: QYNAPSE
Jul 28, 2025, 10:13 ET Village Super League Kembali Digelar di Rongjiang, Wilayah yang Sempat Dilanda Banjir: Simbol dari Semangat Pantang Menyerah
GUIYANG, Tiongkok, 28 Juli 2025 /PRNewswire/ -- Artikel berita dari CNS: Kurang dari satu bulan sejak bencana banjir yang membenamkan stadion ikonik, Village Super League kembali hadir pada 26 Juli lalu. Kebangkitan stadion ini, melambangkan kegigihan, terwujud
More news about: CNS
Jul 28, 2025, 09:10 ET XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
uneventfully and has now entered the formal follow-up period. XellSmart has achieved a significant milestone in global central nervous system (CNS) injury repair — having completed the world's first patient dosing in its China registrational clinical trial. This
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Jul 28, 2025, 09:02 ET Alamar Biosciences 於阿茲海默症協會國際會議 (AAIC) 中，展示嶄新腦源性 pTau 數據
此演講將展示來自「1946 年出生患者組」的數據，該患者組利用 NULISAseq™ CNS Disease Panel 120 於症狀前和阿茲海默症診斷後樣本中，而發現全腦源性 pTau 亞型。這突顯確診阿茲海默症數年前，腦源性 pTau 具備卓越預測能力。疾病進展的關聯： 此數據將展示腦源性 pTau 水平與澱粉樣蛋白和 Tau PET 成像之間的關聯神經病理學與 AD 合併病理學的生物標記：獨特屍檢確診病理學患者組的分析中，利用 NULISAseq™ CNS Disease Panel 120 而確定檢測神經病理和 AD 合併病理的生物標記。臨床前研究：在來自多種
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:12 ET Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:12 ET Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)
year's AAIC marks the first public presentation of robust clinical data generated using NULISA to measure brain-derived pTaus alongside over 120 key CNS disease-related proteins, an achievement that could accelerate both early detection and therapeutic monitoring in Alzheimer's and related neurodegenerative
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:12 ET Alamar Biosciences präsentiert bahnbrechende, aus dem Gehirn gewonnene pTau-Daten auf der Alzheimer's Association International Conference (AAIC)
abgeleitete pTau-Leistung: Die Präsentation wird Daten aus der Geburtskohorte von 1946 vorstellen, die die neuen pTau-Isoformen aus dem Gehirn unter Verwendung des NULISAseq™ CNS Disease Panel 120 sowohl in prä-symptomatischen als auch in post-AD-Diagnoseproben zeigen und die überlegene Fähigkeit von pTaus aus dem Gehirn hervorheben,
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:12 ET 알라마 바이오사이언스, 알츠하이머 협회 국제학술대회(AAIC)에서 획기적인 뇌 유래 pTau 데이터 공개
샘플에서 NULISAseq™ CNS 질환 패널 120을 사용해 새로운 뇌 유래 pTau 동형 단백질을 측정한 데이터를 공개한다. 해당 데이터는 알츠하이머병 진단 수년 전부터 뇌 유래 pTau가 질병을 예측할 수 있는 우수한 능력을 보여준다.질병 진행과의 상관관계: 뇌유래 pTau 수치와 아밀로이드 및 타우 PET 영상 데이터 간의 상관관계를 제시한다.신경병리 및 알츠하이머병 공동 병리 바이오마커: NULISAseq™ CNS 질환 패널 120을 사용하여
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:12 ET À l'occasion de la conférence internationale de l'Alzheimer's Association (AAIC) Alamar Biosciences présente des données pionnières sur le pTau dérivé du cerveau
présentation exposera les données de la cohorte de naissance de 1946 présentant les nouvelles isoformes pTau dérivées du cerveau à l'aide du NULISAseq™ CNS Disease Panel 120 dans les échantillons présymptomatiques et post-diagnostic de la maladie d'Alzheimer, soulignant la capacité supérieure des pTau dérivés
More news about: Alamar Biosciences, Inc.
Jul 28, 2025, 08:00 ET Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
from the wealth of data collected both at home and in the clinic in CNS-101," said Dr. Emer MacSweeney, Co-Founder & CEO of Re:Cognition Health's Brain and Mind Clinics which served as a leading CNS-101 clinical site. "The burden on study participants and patients is
More news about: Cumulus Neuroscience
Jul 28, 2025, 08:00 ET MapLight Therapeutics Announces $372.5 Million Series D Financing
substantial unmet medical need in schizophrenia, ADP and other CNS indications," said Nanna Lüneborg. "We are excited to partner with the outstanding team and investor syndicate at MapLight to fuel these important new innovations in the CNS space," said Josh Richardson,
More news about: MapLight Therapeutics, Inc.
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Jul 25, 2025, 08:00 ET Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
sub-divided into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) About VORANIGOVORANIGO is an isocitrate
More news about: Servier Pharmaceuticals
Jul 25, 2025, 07:30 ET Taiho Oncology Announces Acceptance of Abstract for Zipalertinib at the ESMO Congress 2025
CEST a.m. on Oct. 13, 2025. Title: Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon MutationsAbstract
More news about: Taiho Oncology